Controlling timing and location in vaccines

[1]  R. Garcea,et al.  Single-administration, thermostable human papillomavirus vaccines prepared with atomic layer deposition technology , 2020, npj Vaccines.

[2]  R. Garcea,et al.  Single-administration, thermostable human papillomavirus vaccines prepared with atomic layer deposition technology , 2020, npj Vaccines.

[3]  D. Irvine,et al.  Pharmacokinetic tuning of protein–antigen fusions enhances the immunogenicity of T-cell vaccines , 2020, Nature Biomedical Engineering.

[4]  Ftlo Bonin-Cecelia,et al.  Phase II: , 2020, The Power of Accountability.

[5]  Paul Rogers,et al.  Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients , 2020, bioRxiv.

[6]  F. Krammer,et al.  SARS-CoV-2 Vaccines: Status Report , 2020, Immunity.

[7]  N. Lurie,et al.  Developing Covid-19 Vaccines at Pandemic Speed. , 2020, The New England journal of medicine.

[8]  R. Wyatt,et al.  Route of Vaccine Administration Alters Antigen Trafficking but Not Innate or Adaptive Immunity. , 2020, Cell reports.

[9]  A. Rodal,et al.  The Impact of Sustained Immunization Regimens on the Antibody Response to Oligomannose Glycans , 2020, ACS chemical biology.

[10]  Daniel W. Kulp,et al.  Engineered immunogen binding to alum adjuvant enhances humoral immunity , 2020, Nature Medicine.

[11]  J. Mascola,et al.  Next-generation influenza vaccines: opportunities and challenges , 2020, Nature Reviews Drug Discovery.

[12]  N. Drager,et al.  The status of tuberculosis vaccine development. , 2020, The Lancet. Infectious diseases.

[13]  M. Swartz,et al.  Lymphatic endothelial cells prime naïve CD8+ T cells into memory cells under steady-state conditions , 2020, Nature Communications.

[14]  Angelo S. Mao,et al.  A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia , 2020, Nature Biomedical Engineering.

[15]  C. Drake,et al.  Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T cell immunity to tumor antigens , 2019, Nature Biotechnology.

[16]  J. Kehrl,et al.  An integrin/MFG-E8 shuttle loads HIV-1 viral-like particles onto follicular dendritic cells in mouse lymph node , 2019, eLife.

[17]  R. Weiss,et al.  Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  D. Irvine,et al.  Rapid Germinal Center and Antibody Responses in Non-human Primates after a Single Nanoparticle Vaccine Immunization , 2019, Cell reports.

[19]  J. Mascola,et al.  Vaccination with Glycan-Modified HIV NFL Envelope Trimer-Liposomes Elicits Broadly Neutralizing Antibodies to Multiple Sites of Vulnerability , 2019, Immunity.

[20]  B. Lambrecht,et al.  Potent lymphatic translocation and spatial control over innate immune activation by polymer-lipid amphiphile conjugates of small molecule TLR7/8 agonists. , 2019, Angewandte Chemie.

[21]  B. Narasimhan,et al.  Single-Dose Combination Nanovaccine Induces Both Rapid and Long-Lived Protection Against Pneumonic Plague. , 2019, Acta biomaterialia.

[22]  D. Baker,et al.  Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle , 2019, Nature Communications.

[23]  W. Chan,et al.  Nanoparticle size influences antigen retention and presentation in lymph node follicles for humoral immunity. , 2019, Nano letters.

[24]  Douglas E. Jones,et al.  Sustained antigen release polyanhydride-based vaccine platform for immunization against bovine brucellosis , 2019, Heliyon.

[25]  Daniel W. Kulp,et al.  Protein engineering and particulate display of B-cell epitopes to facilitate development of novel vaccines. , 2019, Current opinion in immunology.

[26]  William R. Schief,et al.  Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination , 2019, Proceedings of the National Academy of Sciences.

[27]  D. Irvine,et al.  Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor , 2019, Science.

[28]  Joe J. Senn,et al.  mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. , 2019, Vaccine.

[29]  John P. Moore,et al.  Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence , 2019, Nature Communications.

[30]  S. Thomas,et al.  Material design for lymph node drug delivery , 2019, Nature Reviews Materials.

[31]  Daniel W. Kulp,et al.  Slow Delivery Immunization Enhances HIV Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance , 2018, Cell.

[32]  M. Benhamou,et al.  Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools , 2019, Front. Immunol..

[33]  J. Crecente‐Campo,et al.  Polysaccharide Nanoparticles Can Efficiently Modulate the Immune Response against an HIV Peptide Antigen , 2019, ACS nano.

[34]  Daniel G Anderson,et al.  Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  J. Yewdell,et al.  Lymph Node Conduits Transport Virions for Rapid T Cell Activation , 2019, Nature Immunology.

[36]  David Baker,et al.  Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus , 2019, Cell.

[37]  B. Narasimhan,et al.  Single dose combination nanovaccine provides protection against influenza A virus in young and aged mice. , 2019, Biomaterials science.

[38]  P. Santamaria,et al.  Antigen-specific therapeutic approaches for autoimmunity , 2019, Nature Biotechnology.

[39]  Darrell J Irvine,et al.  Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers , 2019, Science.

[40]  T. Monath,et al.  rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment , 2019, Vaccine: X.

[41]  Jason S McLellan,et al.  Structure-Based Vaccine Antigen Design. , 2019, Annual review of medicine.

[42]  Y. Wen,et al.  From therapeutic antibodies to immune complex vaccines , 2019, npj Vaccines.

[43]  Daniel W. Kulp,et al.  Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers , 2019, Immunity.

[44]  Mark Kelley,et al.  Endosomolytic Polymersomes Increase the Activity of Cyclic Dinucleotide STING Agonists to Enhance Cancer Immunotherapy , 2018, Nature Nanotechnology.

[45]  A. Perelson,et al.  Regulation of T cell expansion by antigen presentation dynamics , 2018, Proceedings of the National Academy of Sciences.

[46]  A. Aldovini,et al.  Mucosal Vaccine Approaches for Prevention of HIV and SIV Transmission. , 2019, Current immunology reviews.

[47]  Adriana Baz Morelli,et al.  A Novel Cellular Pathway of Antigen Presentation and CD4 T Cell Activation in vivo , 2018, Front. Immunol..

[48]  Dong Soo Yun,et al.  Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes , 2018, Scientific Reports.

[49]  John T. Wilson,et al.  Poly(propylacrylic acid)-peptide nanoplexes as a platform for enhancing the immunogenicity of neoantigen cancer vaccines. , 2018, Biomaterials.

[50]  C. Mirkin,et al.  RNA-Based Immunostimulatory Liposomal Spherical Nucleic Acids as Potent TLR7/8 Modulators. , 2018, Small.

[51]  C. Fox,et al.  Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want , 2018, npj Vaccines.

[52]  R. Coler,et al.  A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  Rino Rappuoli,et al.  Correlates of adjuvanticity: A review on adjuvants in licensed vaccines. , 2018, Seminars in immunology.

[54]  J. Ortega,et al.  A Malaria Vaccine Adjuvant Based on Recombinant Antigen Binding to Liposomes , 2018, Nature Nanotechnology.

[55]  V. Ward,et al.  Virus-like particle vaccines: immunology and formulation for clinical translation , 2018, Expert review of vaccines.

[56]  J. Rudra,et al.  Nanoscale Peptide Self-assemblies Boost BCG-primed Cellular Immunity Against Mycobacterium tuberculosis , 2018, Scientific Reports.

[57]  D. Mooney,et al.  Biomaterial-assisted targeted modulation of immune cells in cancer treatment , 2018, Nature Materials.

[58]  J. Rayner,et al.  Malaria Vaccines: Recent Advances and New Horizons , 2018, Cell host & microbe.

[59]  G. Kelsoe,et al.  Germinal center responses to complex antigens , 2018, Immunological reviews.

[60]  Rebecca L. Holden,et al.  Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability , 2018, Cancer Immunology Research.

[61]  D. Marciani.  Elucidating the Mechanisms of Action of Saponin-Derived Adjuvants. , 2018, Trends in pharmacological sciences.

[62]  Kevin J. McHugh,et al.  Stabilized single-injection inactivated polio vaccine elicits a strong neutralizing immune response , 2018, Proceedings of the National Academy of Sciences.

[63]  D. Hawke,et al.  Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response , 2018, The Journal of Immunology.

[64]  A. Middelberg,et al.  Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy , 2018, The Journal of clinical investigation.

[65]  K. Shull,et al.  Sustained micellar delivery via inducible transitions in nanostructure morphology , 2018, Nature Communications.

[66]  D. Weissman,et al.  mRNA vaccines — a new era in vaccinology , 2018, Nature Reviews Drug Discovery.

[67]  U. Şahin,et al.  Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[68]  Xun Sun,et al.  Turning the Old Adjuvant from Gel to Nanoparticles to Amplify CD8+ T Cell Responses , 2017, Advanced science.

[69]  Kevin J. McHugh,et al.  Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination , 2017, Vaccine.

[70]  Xun Sun,et al.  Lymph node targeting strategies to improve vaccination efficacy , 2017, Journal of controlled release : official journal of the Controlled Release Society.

[71]  R. Friedman,et al.  Migratory dendritic cells acquire and present lymphatic endothelial cell-archived antigens during lymph node contraction , 2017, Nature Communications.

[72]  H. Shroff,et al.  Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy , 2017, Nature Communications.

[73]  M. Nussenzweig,et al.  The microanatomic segregation of selection by apoptosis in the germinal center , 2017, Science.

[74]  Ronald N Germain,et al.  Dendritic cell and antigen dispersal landscapes regulate T cell immunity , 2017, The Journal of experimental medicine.

[75]  O. Golani,et al.  Active dissemination of cellular antigens by DCs facilitates CD8+ T‐cell priming in lymph nodes , 2017, European journal of immunology.

[76]  Robert Langer,et al.  Fabrication of fillable microparticles and other complex 3D microstructures , 2017, Science.

[77]  P. Palese,et al.  Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization , 2017, Proceedings of the National Academy of Sciences.

[78]  P. Marrack,et al.  Old and new adjuvants. , 2017, Current opinion in immunology.

[79]  S. Crotty,et al.  Germinal center enhancement by extended antigen availability. , 2017, Current opinion in immunology.

[80]  Gabriella Sármay,et al.  Antigen-specific immunotherapies in rheumatic diseases , 2017, Nature Reviews Rheumatology.

[81]  P. Boyaka.  Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems , 2017, The Journal of Immunology.

[82]  Daniel W. Kulp,et al.  Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches , 2017, Immunity.

[83]  R. Koup,et al.  Vaccine priming is restricted to draining lymph nodes and controlled by adjuvant-mediated antigen uptake , 2017, Science Translational Medicine.

[84]  Soong Ho Um,et al.  Synthetic vaccine nanoparticles target to lymph node triggering enhanced innate and adaptive antitumor immunity. , 2017, Biomaterials.

[85]  S. Baekkeskov,et al.  Bioengineering strategies for inducing tolerance in autoimmune diabetes , 2017, Advanced drug delivery reviews.

[86]  Wei Xue,et al.  pH Sensitive phosphorylated chitosan hydrogel as vaccine delivery system for intramuscular immunization , 2017, Journal of biomaterials applications.

[87]  Zhijian J. Chen,et al.  A STING-Activating Nanovaccine for Cancer Immunotherapy , 2017, Nature nanotechnology.

[88]  B. Haynes,et al.  Developing an HIV vaccine , 2017, Science.

[89]  Robert Langer,et al.  Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy. , 2017, Nano letters.

[90]  A. Levine,et al.  Plant viral nanoparticles-based HER2 vaccine: Immune response influenced by differential transport, localization and cellular interactions of particulate carriers. , 2017, Biomaterials.

[91]  S. Thomas,et al.  Flexible Macromolecule versus Rigid Particle Retention in the Injected Skin and Accumulation in Draining Lymph Nodes Are Differentially Influenced by Hydrodynamic Size. , 2017, ACS biomaterials science & engineering.

[92]  James R. Swartz,et al.  Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery , 2017, Bioengineering & translational medicine.

[93]  S. Crotty,et al.  Tfh cells and HIV bnAbs, an immunodominance model of the HIV neutralizing antibody generation problem , 2017, Immunological reviews.

[94]  J. Moon,et al.  Designer vaccine nanodiscs for personalized cancer immunotherapy , 2016, Nature materials.

[95]  P. Malyala,et al.  Polymeric Particles as Vaccine Delivery Systems , 2017 .

[96]  J. Vekemans,et al.  The Development of the Adjuvant System AS01: A Combination of Two Immunostimulants MPL and QS-21 in Liposomes , 2017 .

[97]  Zeinab H. Helal,et al.  Vaccination with self-adjuvanted protein nanoparticles provides protection against lethal influenza challenge. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[98]  Abdelatif Elouahabi,et al.  Central Role of CD169+ Lymph Node Resident Macrophages in the Adjuvanticity of the QS-21 Component of AS01 , 2016, Scientific Reports.

[99]  Koen van der Maaden,et al.  Repeated fractional intradermal dosing of an inactivated polio vaccine by a single hollow microneedle leads to superior immune responses. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[100]  David J. Mooney,et al.  Designing hydrogels for controlled drug delivery. , 2016, Nature reviews. Materials.

[101]  Daniel G. Anderson,et al.  Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination , 2016, Proceedings of the National Academy of Sciences.

[102]  M. Miley,et al.  Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses , 2016, PLoS neglected tropical diseases.

[103]  Daniel W. Kulp,et al.  Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice , 2016, Science.

[104]  G. Victora,et al.  Germinal Center B Cell Dynamics. , 2016, Immunity.

[105]  Lidia Oostvogels,et al.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. , 2016, The New England journal of medicine.

[106]  A. Schambach,et al.  Viral and Synthetic RNA Vector Technologies and Applications. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

[107]  C. Exley,et al.  Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations , 2016, Scientific Reports.

[108]  S. Miller,et al.  Immune Tolerance for Autoimmune Disease and Cell Transplantation. , 2016, Annual review of biomedical engineering.

[109]  B. Lambrecht,et al.  pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation , 2016, Proceedings of the National Academy of Sciences.

[110]  Daniel G. Anderson,et al.  Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose , 2016, Proceedings of the National Academy of Sciences.

[111]  D. Burton,et al.  Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles , 2016, Nature Communications.

[112]  J. Kranich,et al.  How Follicular Dendritic Cells Shape the B-Cell Antigenome , 2016, Front. Immunol..

[113]  Özlem Türeci,et al.  Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy , 2016, Nature.

[114]  R. Wyatt,et al.  High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. , 2016, Cell reports.

[115]  M. Ernstoff,et al.  A Phase II Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-Treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand. , 2016 .

[116]  E. Hak,et al.  Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability , 2016, PloS one.

[117]  R. Rappuoli,et al.  Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design , 2016, The Journal of experimental medicine.

[118]  L. Beura,et al.  Shortened Intervals during Heterologous Boosting Preserve Memory CD8 T Cell Function but Compromise Longevity , 2016, Journal of Immunology.

[119]  Joseph G. Jardine,et al.  HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen , 2016, Science.

[120]  Takuya Nojima,et al.  Complex Antigens Drive Permissive Clonal Selection in Germinal Centers. , 2016, Immunity.

[121]  N. Petrovsky,et al.  Molecular mechanisms for enhanced DNA vaccine immunogenicity , 2016, Expert review of vaccines.

[122]  Darrell J Irvine,et al.  Beyond antigens and adjuvants: formulating future vaccines. , 2016, The Journal of clinical investigation.

[123]  A. Bolhassani,et al.  Prime-boost vaccine strategy against viral infections: Mechanisms and benefits. , 2016, Vaccine.

[124]  Michael Dallas,et al.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial , 2015, The Lancet.

[125]  R. Weiss,et al.  N(1)-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[126]  D. Weissman,et al.  Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[127]  Shixia Wang,et al.  Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants* , 2015, The Journal of Biological Chemistry.

[128]  Guanghui Ma,et al.  Polymeric micro/nanoparticles: Particle design and potential vaccine delivery applications. , 2015, Vaccine.

[129]  K. Tsumoto,et al.  Structural analysis of Fc/FcγR complexes: a blueprint for antibody design , 2015, Immunological reviews.

[130]  Michael Y. Gerner,et al.  In vivo characterization of the physicochemical properties of TLR agonist delivery that enhance vaccine immunogenicity , 2015, Nature Biotechnology.

[131]  Christopher J. H. Porter,et al.  From sewer to saviour — targeting the lymphatic system to promote drug exposure and activity , 2015, Nature Reviews Drug Discovery.

[132]  S. Yerly,et al.  The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. , 2015, The Lancet. Infectious diseases.

[133]  D. Irvine,et al.  Synthetic Nanoparticles for Vaccines and Immunotherapy. , 2015, Chemical reviews.

[134]  John P. Moore,et al.  Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity , 2015, Retrovirology.

[135]  John-Arne Røttingen,et al.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial , 2015, The Lancet.

[136]  David J Mooney,et al.  Injectable cryogel-based whole-cell cancer vaccines , 2015, Nature Communications.

[137]  M. Nussenzweig,et al.  T cell help controls the speed of the cell cycle in germinal center B cells , 2015, Science.

[138]  John P. Moore,et al.  Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity , 2015, Journal of Virology.

[139]  David Nemazee,et al.  Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.

[140]  D. Jackson,et al.  A single dose biodegradable vaccine depot that induces persistently high levels of antibody over a year. , 2015, Biomaterials.

[141]  J. DeSimone,et al.  Rapid and Persistent Delivery of Antigen by Lymph Node Targeting PRINT Nanoparticle Vaccine Carrier To Promote Humoral Immunity. , 2015, Molecular pharmaceutics.

[142]  K. Lundstrom.  Alphaviruses in Gene Therapy , 2015, Viruses.

[143]  Gregory L. Szeto,et al.  Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants. , 2015, The Journal of clinical investigation.

[144]  N. Garçon,et al.  Vaccine Adjuvants: from 1920 to 2015 and Beyond , 2015, Vaccines.

[145]  Shibo Jiang,et al.  Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus , 2015, Human vaccines & immunotherapeutics.

[146]  R. Reljic,et al.  Novel vaccination approach for dengue infection based on recombinant immune complex universal platform. , 2015, Vaccine.

[147]  S. Jalkanen,et al.  The endothelial protein PLVAP in lymphatics controls the entry of lymphocytes and antigens into lymph nodes , 2015, Nature Immunology.

[148]  A. Iwasaki,et al.  Control of adaptive immunity by the innate immune system , 2015, Nature Immunology.

[149]  C. Mirkin,et al.  Immunomodulatory spherical nucleic acids , 2015, Proceedings of the National Academy of Sciences.

[150]  Daniel E. Zak,et al.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling. , 2015, The Journal of clinical investigation.

[151]  R. Drezek,et al.  In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. , 2015, Small.

[152]  Philip D. Hodgkin,et al.  The generation of antibody-secreting plasma cells , 2015, Nature Reviews Immunology.

[153]  E. De Gregorio,et al.  Vaccine Adjuvant MF59 Promotes Retention of Unprocessed Antigen in Lymph Node Macrophage Compartments and Follicular Dendritic Cells , 2015, The Journal of Immunology.

[154]  Michael Y. Gerner,et al.  Strategically localized dendritic cells promote rapid T cell responses to lymph-borne particulate antigens. , 2015, Immunity.

[155]  Ron Weiss,et al.  Synthetic biology devices and circuits for RNA-based ‘smart vaccines’: a propositional review , 2015, Expert review of vaccines.

[156]  Youngjin Choi,et al.  Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy , 2014, Nature Biotechnology.

[157]  J. Aronson.  Safety , 2009, BMJ : British Medical Journal.

[158]  Ronnie H. Fang,et al.  Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. , 2015, Nano letters.

[159]  J. Schenkel,et al.  Tissue-resident memory T cells. , 2014, Immunity.

[160]  T. Ottenhoff,et al.  A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. , 2014, Vaccine.

[161]  M. Cooke,et al.  Rational design of small molecules as vaccine adjuvants , 2014, Science Translational Medicine.

[162]  Arthur Fridman,et al.  Titrating T‐Cell Epitopes within Self‐Assembled Vaccines Optimizes CD4+ Helper T Cell and Antibody Outputs , 2014, Advanced healthcare materials.

[163]  C. Löwik,et al.  Targeting nanoparticles to CD40, DEC-205 or CD11c molecules on dendritic cells for efficient CD8(+) T cell response: a comparative study. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[164]  Elena Stylianou,et al.  Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG. , 2014, Plant biotechnology journal.

[165]  M. Nussenzweig,et al.  Dynamic signaling by T follicular helper cells during germinal center B cell selection , 2014, Science.

[166]  B. Lambrecht,et al.  Enhancement of Adaptive Immunity by the Human Vaccine Adjuvant AS01 Depends on Activated Dendritic Cells , 2014, The Journal of Immunology.

[167]  K. Okuda,et al.  Developments in Viral Vector-Based Vaccines , 2014, Vaccines.

[168]  S. Turley,et al.  Trans-nodal migration of resident dendritic cells into medullary interfollicular regions initiates immunity to influenza vaccine , 2014, The Journal of experimental medicine.

[169]  F. Klauschen,et al.  T-cell-receptor-dependent signal intensity dominantly controls CD4(+) T cell polarization In Vivo. , 2014, Immunity.

[170]  Joel H. Collier,et al.  Gradated assembly of multiple proteins into supramolecular nanomaterials , 2014, Nature materials.

[171]  Michel C. Nussenzweig,et al.  Clonal selection in the germinal centre by regulated proliferation and hypermutation , 2014, Nature.

[172]  M. Dhodapkar,et al.  Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205 , 2014, Science Translational Medicine.

[173]  E. Bergmann-Leitner,et al.  Adjuvants in the Driver’s Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune Potentiators , 2014, Vaccines.

[174]  S. Koernig,et al.  Inflammasome-Dependent and -Independent IL-18 Production Mediates Immunity to the ISCOMATRIX Adjuvant , 2014, The Journal of Immunology.

[175]  P. Choyke,et al.  Tracking the Luminal Exposure and Lymphatic Drainage Pathways of Intravaginal and Intrarectal Inocula Used in Nonhuman Primate Models of HIV Transmission , 2014, PloS one.

[176]  Jerome H. Kim,et al.  HIV-1 vaccines , 2014, Human vaccines & immunotherapeutics.

[177]  N. Sardesai,et al.  DNA and Protein Co-Immunization Improves the Magnitude and Longevity of Humoral Immune Responses in Macaques , 2014, PloS one.

[178]  Gregory L. Szeto,et al.  Structure-based programming of lymph-node targeting in molecular vaccines , 2014, Nature.

[179]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[180]  P. Højrup,et al.  Aluminum Hydroxide Adjuvant Differentially Activates the Three Complement Pathways with Major Involvement of the Alternative Pathway , 2013, PloS one.

[181]  Fangjia Lu,et al.  Kinetics of the inflammatory response following intramuscular injection of aluminum adjuvant. , 2013, Vaccine.

[182]  S. Reed,et al.  HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. , 2013, Vaccine.

[183]  J. Collier,et al.  A Self‐Adjuvanting Supramolecular Vaccine Carrying a Folded Protein Antigen , 2013, Advanced healthcare materials.

[184]  Ronnie H. Fang,et al.  Surface Functionalization of Gold Nanoparticles with Red Blood Cell Membranes , 2013, Advanced materials.

[185]  T. Kirchhausen,et al.  Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. , 2013, Immunity.

[186]  P. Andersen,et al.  Control of Chronic Mycobacterium tuberculosis Infection by CD4 KLRG1− IL-2–Secreting Central Memory Cells , 2013, The Journal of Immunology.

[187]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[188]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[189]  J. DeSimone,et al.  Development of a nanoparticle-based influenza vaccine using the PRINT technology. , 2013, Nanomedicine : nanotechnology, biology, and medicine.

[190]  F. Sallusto,et al.  Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype. , 2013, Immunity.

[191]  Michael Meyer-Hermann,et al.  Germinal center B cells govern their own fate via antibody feedback , 2013, The Journal of experimental medicine.

[192]  C. Liu,et al.  Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.

[193]  G. Nabel.  Designing tomorrow's vaccines. , 2013, The New England journal of medicine.

[194]  P. Hoeprich,et al.  Colocalized delivery of adjuvant and antigen using nanolipoprotein particles enhances the immune response to recombinant antigens. , 2013, Journal of the American Chemical Society.

[195]  N. Sardesai,et al.  DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge , 2013, Proceedings of the National Academy of Sciences.

[196]  S. Schwendeman,et al.  Active self-healing encapsulation of vaccine antigens in PLGA microspheres. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[197]  M. Burchill,et al.  T cell vaccinology: exploring the known unknowns. , 2013, Vaccine.

[198]  R. Coler,et al.  Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy , 2012, Influenza and other respiratory viruses.

[199]  D. Weissman,et al.  HPLC purification of in vitro transcribed long RNA. , 2013, Methods in molecular biology.

[200]  N. Petrovsky,et al.  The future of human DNA vaccines. , 2012, Journal of biotechnology.

[201]  S. Schwendeman,et al.  Self-healing microencapsulation of biomacromolecules without organic solvents. , 2012, Angewandte Chemie.

[202]  N. Sardesai,et al.  Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses , 2012, Science Translational Medicine.

[203]  Satish Mishra,et al.  Self-assembled peptide nanofibers raising durable antibody responses against a malaria epitope. , 2012, Biomaterials.

[204]  J. Brewer,et al.  Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro , 2012, Immunology letters.

[205]  Thomas Krucker,et al.  Nonviral delivery of self-amplifying RNA vaccines , 2012, Proceedings of the National Academy of Sciences.

[206]  M. Kool,et al.  Alum adjuvant: some of the tricks of the oldest adjuvant. , 2012, Journal of medical microbiology.

[207]  Eric Stern,et al.  Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype. , 2012, Biomaterials.

[208]  Thomas B Kepler,et al.  B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.

[209]  M. Bachmann,et al.  Innate Immunity Mediates Follicular Transport of Particulate but Not Soluble Protein Antigen , 2012, The Journal of Immunology.

[210]  Wei Wei,et al.  Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization. , 2012, Biomaterials.

[211]  Paul Garside,et al.  Antigen depot is not required for alum adjuvanticity , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[212]  D. Irvine,et al.  Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[213]  D. Irvine,et al.  Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand Tfh cells and promote germinal center induction , 2012, Proceedings of the National Academy of Sciences.

[214]  W. Blattner,et al.  Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine with or without IL-12 and/or IL-15 Plasmid Cytokine Adjuvant in Healthy, HIV-1 Uninfected Adults , 2012, PloS one.

[215]  Mary E Napier,et al.  PRINT: a novel platform toward shape and size specific nanoparticle theranostics. , 2011, Accounts of chemical research.

[216]  D. Irvine,et al.  In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles , 2011, Proceedings of the National Academy of Sciences.

[217]  D. Weissman,et al.  Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA , 2011, Nucleic acids research.

[218]  D. Weissman,et al.  Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L , 2011, Nucleic acids research.

[219]  D. Mooney,et al.  Relationship of vaccine efficacy to the kinetics of DC and T-cell responses induced by PLG-based cancer vaccines , 2011, Biomatter.

[220]  N. Sardesai,et al.  Electroporation delivery of DNA vaccines: prospects for success. , 2011, Current opinion in immunology.

[221]  Ping Zhang,et al.  Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity , 2011, Nature Medicine.

[222]  Y. Perrie,et al.  Liposomal vaccine delivery systems , 2011, Expert opinion on drug delivery.

[223]  R. Maul,et al.  Different B Cell Populations Mediate Early and Late Memory During an Endogenous Immune Response , 2011, Science.

[224]  B. Narasimhan,et al.  Design of a Protective Single-Dose Intranasal Nanoparticle-Based Vaccine Platform for Respiratory Infectious Diseases , 2011, PloS one.

[225]  Mario Cortese,et al.  Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. , 2011, Vaccine.

[226]  N. Letvin,et al.  Modulation of Plasmid DNA Vaccine Antigen Clearance by Caspase 12 RNA Interference Potentiates Vaccination , 2011, Clinical and Vaccine Immunology.

[227]  B. Malissen,et al.  Langerin+ Dermal Dendritic Cells Are Critical for CD8+ T Cell Activation and IgH γ-1 Class Switching in Response to Gene Gun Vaccines , 2011, The Journal of Immunology.

[228]  B. Nelson,et al.  Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:C). , 2011, Vaccine.

[229]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[230]  S. Vasan,et al.  Immunogenicity, safety, biodistribution and persistence of ADVAX, a prophylactic DNA vaccine for HIV-1, delivered by in vivo electroporation. , 2011, Vaccine.

[231]  John Steel,et al.  Programming the magnitude and persistence of antibody responses with innate immunity , 2010, Nature.

[232]  M. Kami,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010 .

[233]  J. Cyster.  B cell follicles and antigen encounters of the third kind , 2010, Nature Immunology.

[234]  Margaret A. Liu,et al.  Immunologic basis of vaccine vectors. , 2010, Immunity.

[235]  M. D. de Veer,et al.  The kinetics of soluble and particulate antigen trafficking in the afferent lymph, and its modulation by aluminum-based adjuvant. , 2010, Vaccine.

[236]  L. Downs,et al.  Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers , 2010, Cancer Immunology, Immunotherapy.

[237]  Ö. Türeci,et al.  Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo , 2010, Gene Therapy.

[238]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[239]  Yvonne Perrie,et al.  Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[240]  D. Burton,et al.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions. , 2010, Current opinion in immunology.

[241]  S. Plotkin.  Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[242]  Siamon Gordon,et al.  Capture of influenza by medullary dendritic cells via SIGN-R1 is essential for humoral immunity in draining lymph nodes , 2010, Nature Immunology.

[243]  M. Green,et al.  Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response. , 2010, Vaccine.

[244]  M. Jenkins,et al.  A Protease-Dependent Mechanism for Initiating T-Dependent B Cell Responses to Large Particulate Antigens , 2010, The Journal of Immunology.

[245]  T. Mitchell,et al.  A detailed characterisation of the distribution and presentation of DNA vaccine encoded antigen , 2010, Vaccine.

[246]  T. Ficht,et al.  Polymeric particles in vaccine delivery. , 2010, Current opinion in microbiology.

[247]  S. F. Gonzalez,et al.  Conduits Mediate Transport of Low-molecular-weight Antigen to Lymph Node Follicles , 2010 .

[248]  Jangwook P. Jung,et al.  A self-assembling peptide acting as an immune adjuvant , 2009, Proceedings of the National Academy of Sciences.

[249]  David J Mooney,et al.  In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice , 2009, Science Translational Medicine.

[250]  R. Veenhoven,et al.  IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. , 2009, Vaccine.

[251]  R. Parks,et al.  Persistence of Transgene Expression Influences CD8+ T-Cell Expansion and Maintenance following Immunization with Recombinant Adenovirus , 2009, Journal of Virology.

[252]  C. Berking,et al.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. , 2009, The Journal of clinical investigation.

[253]  S. Radulović,et al.  The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. , 2009, Vaccine.

[254]  Elizabeth E Gray,et al.  Immune complex relay by subcapsular sinus macrophages and non-cognate B cells drives antibody affinity maturation , 2009, Nature Immunology.

[255]  S. Gambhir,et al.  A Potent, Imaging Adenoviral Vector Driven by the Cancer-selective Mucin-1 Promoter That Targets Breast Cancer Metastasis , 2009, Clinical Cancer Research.

[256]  H. HogenEsch,et al.  Comparative analysis of vector biodistribution, persistence and gene expression following intravenous delivery of bovine, porcine and human adenoviral vectors in a mouse model. , 2009, Virology.

[257]  U. V. von Andrian,et al.  Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. , 2009, Immunity.

[258]  J. Tschopp,et al.  Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome , 2009, Proceedings of the National Academy of Sciences.

[259]  Hiroki Kato,et al.  Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[260]  H. Hammad,et al.  Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome , 2008, The Journal of Immunology.

[261]  M. Horwitz,et al.  A Replication-Limited Recombinant Mycobacterium bovis BCG Vaccine against Tuberculosis Designed for Human Immunodeficiency Virus-Positive Persons Is Safer and More Efficacious than BCG , 2008, Infection and Immunity.

[262]  K. Rock,et al.  Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization , 2008, Nature Immunology.

[263]  T. Wu,et al.  RNA interference-mediated in vivo silencing of fas ligand as a strategy for the enhancement of DNA vaccine potency. , 2008, Human gene therapy.

[264]  D. Peabody,et al.  Immunogenic display of diverse peptides on virus-like particles of RNA phage MS2. , 2008, Journal of molecular biology.

[265]  Richard A. Flavell,et al.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.

[266]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[267]  T. Kündig,et al.  Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.

[268]  N. Letvin,et al.  Kinetics of Recombinant Adenovirus Type 5, Vaccinia Virus, Modified Vaccinia Ankara Virus, and DNA Antigen Expression In Vivo and the Induction of Memory T-Lymphocyte Responses , 2008, Clinical and Vaccine Immunology.

[269]  J. Bruder,et al.  Promoters influence the kinetics of transgene expression following adenovector gene delivery , 2008, The journal of gene medicine.

[270]  A. Hauschild,et al.  An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma , 2008, Clinical Cancer Research.

[271]  N. D. Di Paolo,et al.  Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and present them to antiviral B cells , 2007, Nature.

[272]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[273]  T. Phan,et al.  Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells , 2007, Nature Immunology.

[274]  C. Yunis,et al.  Pharmacokinetics of 852A, an Imidazoquinoline Toll‐Like Receptor 7‐Specific Agonist, Following Intravenous, Subcutaneous, and Oral Administrations in Humans , 2007, Journal of clinical pharmacology.

[275]  F. Batista,et al.  B cells acquire particulate antigen in a macrophage-rich area at the boundary between the follicle and the subcapsular sinus of the lymph node. , 2007, Immunity.

[276]  D. Klinman,et al.  Potential of Transfected Muscle Cells to Contribute to DNA Vaccine Immunogenicity1 , 2007, The Journal of Immunology.

[277]  H. HogenEsch,et al.  Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. , 2007, Vaccine.

[278]  Lily Wu,et al.  Differential biodistribution of adenoviral vector in vivo as monitored by bioluminescence imaging and quantitative polymerase chain reaction. , 2006, Human gene therapy.

[279]  Sang-Jun Ha,et al.  Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination. , 2006, Journal of immunology.

[280]  J. S. St. George,et al.  Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. , 2006, Human gene therapy.

[281]  J. Villadangos,et al.  Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. , 2006, Immunity.

[282]  Ronald N. Germain,et al.  Extrafollicular Activation of Lymph Node B Cells by Antigen-Bearing Dendritic Cells , 2006, Science.

[283]  Sai T Reddy,et al.  In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[284]  R. Steinman,et al.  Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses , 2006, The Journal of experimental medicine.

[285]  J. Griffin,et al.  Factors influencing the protective efficacy of a BCG homologous prime-boost vaccination regime against tuberculosis. , 2006, Vaccine.

[286]  P. Kozlowski,et al.  Mucosal vaccines: the promise and the challenge , 2006, Nature Reviews Immunology.

[287]  R. Clynes,et al.  Cell surface recycling of internalized antigen permits dendritic cell priming of B cells. , 2005, Immunity.

[288]  M. Sallberg,et al.  Combinatorial Approach to Hepadnavirus-Like Particle Vaccine Design , 2005, Journal of Virology.

[289]  Christophe Benoist,et al.  Antigen persistence is required throughout the expansion phase of a CD4+ T cell response , 2005, The Journal of experimental medicine.

[290]  P. Robbins,et al.  Immunization with Lentiviral Vector-Transduced Dendritic Cells Induces Strong and Long-Lasting T Cell Responses and Therapeutic Immunity 1 , 2005, The Journal of Immunology.

[291]  C. Porter,et al.  Subcutaneous drug delivery and the role of the lymphatics. , 2005, Drug discovery today. Technologies.

[292]  A. McMichael,et al.  Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. , 2005, Vaccine.

[293]  R. Geahlen,et al.  Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. , 2005, Vaccine.

[294]  Wenlei Jiang,et al.  Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. , 2005, Advanced drug delivery reviews.

[295]  Tae Woo Kim,et al.  Modification of professional antigen-presenting cells with small interfering RNA in vivo to enhance cancer vaccine potency. , 2005, Cancer research.

[296]  Michael Sixt,et al.  The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. , 2005, Immunity.

[297]  P. Gonin,et al.  Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development , 2004, Gene therapy.

[298]  M. Giedlin,et al.  Listeria-based cancer vaccines that segregate immunogenicity from toxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[299]  N. Letvin,et al.  Expression kinetics of the interleukin-2/immunoglobulin (IL-2/Ig) plasmid cytokine adjuvant. , 2004, Vaccine.

[300]  H. Bouwer,et al.  Listeria monocytogenes as a Vaccine Vector: Virulence Attenuation or Existing Antivector Immunity Does Not Diminish Therapeutic Efficacy1 , 2004, The Journal of Immunology.

[301]  R. Steinman,et al.  In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination , 2004, The Journal of experimental medicine.

[302]  Thomas Rades,et al.  Pseudo-ternary phase diagrams of aqueous mixtures of Quil A, cholesterol and phospholipid prepared by the lipid-film hydration method. , 2004, International journal of pharmaceutics.

[303]  A. Supersaxo,et al.  Effect of Molecular Weight on the Lymphatic Absorption of Water-Soluble Compounds Following Subcutaneous Administration , 1990, Pharmaceutical Research.

[304]  G. Belz,et al.  Epidermal Viral Immunity Induced by CD8α+ Dendritic Cells But Not by Langerhans Cells , 2003, Science.

[305]  T. Storni,et al.  Innate Immunity Together with Duration of Antigen Persistence Regulate Effector T Cell Induction , 2003, The Journal of Immunology.

[306]  A. Rudensky,et al.  Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. , 2003, Immunity.

[307]  S. Hem,et al.  Relationship between the degree of antigen adsorption to aluminum hydroxide adjuvant in interstitial fluid and antibody production. , 2003, Vaccine.

[308]  Balaji Narasimhan,et al.  Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery. , 2002, Biomaterials.

[309]  J. Harty,et al.  Programmed contraction of CD8+ T cells after infection , 2002, Nature Immunology.

[310]  A. Moreno,et al.  Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21. , 2002, Vaccine.

[311]  G. Sutter,et al.  Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. , 2001, The Journal of general virology.

[312]  G. Ciliberto,et al.  An improved helper-dependent adenoviral vector allows persistent gene expression after intramuscular delivery and overcomes preexisting immunity to adenovirus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[313]  K. Fujioka,et al.  Collagen minipellet as a controlled release delivery system for tetanus and diphtheria toxoid. , 2001, Vaccine.

[314]  D. Montefiori,et al.  QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. , 2001, Vaccine.

[315]  Eric G. Pamer,et al.  Early Programming of T Cell Populations Responding to Bacterial Infection1 , 2000, The Journal of Immunology.

[316]  Stephen Shaw,et al.  Lymph-Borne Chemokines and Other Low Molecular Weight Molecules Reach High Endothelial Venules via Specialized Conduits While a Functional Barrier Limits Access to the Lymphocyte Microenvironments in Lymph Node Cortex , 2000, The Journal of experimental medicine.

[317]  D. McDonald,et al.  Distribution of DNA Vaccines Determines Their Immunogenicity After Intramuscular Injection in Mice1 , 2000, The Journal of Immunology.

[318]  A. Craiu,et al.  Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[319]  Y. Miyagi,et al.  The Timing of GM-CSF Expression Plasmid Administration Influences the Th1/Th2 Response Induced by an HIV-1-Specific DNA Vaccine1 , 2000, The Journal of Immunology.

[320]  S. Schwendeman,et al.  Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide) , 2000, Nature Biotechnology.

[321]  R. Steinman,et al.  Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. , 1999, Immunity.

[322]  R. Sekulovich,et al.  Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. , 1999, The Journal of infectious diseases.

[323]  R. Germain,et al.  Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization , 1998, The Journal of experimental medicine.

[324]  M. S. Singh,et al.  Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines. , 1998, Advanced drug delivery reviews.

[325]  J L Cleland,et al.  Protein delivery from biodegradable microspheres. , 1997, Pharmaceutical biotechnology.

[326]  R. Gupta,et al.  In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. , 1996, Vaccine.

[327]  Christopher C. Goodnow,et al.  C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity , 1996, Science.

[328]  J. Tamada,et al.  The development of polyanhydrides for drug delivery applications. , 1992, Journal of biomaterials science. Polymer edition.

[329]  B. Bloom.  Vaccines for the Third World , 1989, Nature.

[330]  A. Osterhaus,et al.  Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses , 1984, Nature.

[331]  J L Turk,et al.  Complement activation by aluminium and zirconium compounds. , 1979, Immunology.

[332]  R. Langer,et al.  A single-step immunization by sustained antigen release. , 1979, Journal of immunological methods.

[333]  J. Sprent,et al.  Age-associated epigenetic modifications in human DNA increase its immunogenicity , 2010, Aging.

[334]  W. T. Harrison.  Some Observations on the Use of Alum Precipitated Diphtheria Toxoid. , 1935, American journal of public health and the nation's health.

[335]  A. Glenny,et al.  Rate of Disappearance of Diphtheria Toxoid injected into Rabbits and Guinea-Pigs: Toxoid precipitated with Alum. , 1931 .